EDMONTON, ALBERTA--(Marketwire - June 25, 2009) - Ceapro Inc. (TSX VENTURE: CZO) today announced the granting of options to directors and officers, for a total of 900,000 at the price of $0.13. Of note, Chief Scientific Officer David Fielder and CFO Branko Jankovic each receive 75,000 share options, and each director receives 150,000. These are subject to TSX Venture approval.
Motions carried at the Annual General Meeting of June 10 include the re-election of Board Members: Ed Taylor as Chairman, Gilles Gagnon, Don Oborowsky, Glenn Rourke, and John Zupancic.
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Ceapro Inc.
Branko Jankovic
Chief Financial Officer
(Edmonton): 780.917.8376
bjankovic@ceapro.com
Sun International Communications
Nicole Blanchard, B.Sc., B.Comm.
Managing Partner
(Montreal): 450.973.6600
nicole.blanchard@isuncomm.com
